Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Active Biotech AB ( (SE:ACTI) ) has issued an update.
Active Biotech announced that preclinical data on tasquinimod combined with T cell activation will be presented at the ASH 2025 conference. The data demonstrates enhanced anti-tumor effects in multiple myeloma models, suggesting potential improvements in immunotherapy efficacy. This development could strengthen Active Biotech’s position in the hematological cancer treatment market and offer promising implications for stakeholders.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company has a portfolio that includes tasquinimod and laquinimod, which are small molecule immunomodulators, and naptumomab, a targeted anti-cancer immunotherapy. Active Biotech’s core focus is on the development of tasquinimod for myelofibrosis and multiple myeloma.
YTD Price Performance: -28.70%
Average Trading Volume: 5,791,839
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK95.21M
See more insights into ACTI stock on TipRanks’ Stock Analysis page.